Paper Details

  1. Home
  2. Paper Details

Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.

Author: AllenAlbert J, BusnerJoan, CasatCharles, DunnDavid, HarderDonald, KelseyDouglas, KratochvilChristopher, MichelsonDavid, NewcornJeffrey, SalleeF Randy, SangalR Bart, SaylorKeith, TrappNancy J, WernickeJoachim, WestScott

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Once-daily administration of atomoxetine is an effective treatment for children and adolescents with ADHD. The treatment effect size was similar to those observed in previous atomoxetine studies that used twice-daily dosing.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: The authors assessed the efficacy of once-daily atomoxetine administration in the treatment of children and adolescents with attention deficit hyperactivity disorder (ADHD). METHOD: In a double-blind study, children and adolescents with ADHD (N=171, age range=6-16 years) were randomly as...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1176/appi.ajp.159.11.1896

データ提供：米国国立医学図書館（NLM）

Once-Daily Atomoxetine: An Effective Treatment for ADHD

This study is a beacon of hope for children and adolescents struggling with attention deficit hyperactivity disorder (ADHD). It explores the efficacy of once-daily atomoxetine, a medication commonly used for ADHD, in comparison to a placebo. The study offers encouraging evidence that once-daily atomoxetine is a safe and effective treatment for ADHD.

Atomoxetine: A Promising Treatment for ADHD

The study found that once-daily atomoxetine was superior to placebo in improving symptoms of ADHD. This is significant because it suggests that once-daily dosing can be just as effective as the traditional twice-daily regimen, potentially increasing convenience and adherence for patients. The study also reported a low rate of adverse events, suggesting that atomoxetine is generally well-tolerated.

ADHD Management: Tailoring Treatment to Individual Needs

This research emphasizes the importance of finding the right treatment approach for individuals with ADHD. The study suggests that once-daily atomoxetine is a viable option for many patients, offering a potential alternative to the twice-daily dosing regimen. It's crucial to consider individual needs, preferences, and responses when choosing the best course of treatment for ADHD.

Dr. Camel's Conclusion

This study is a testament to the ongoing progress in understanding and treating ADHD. As a researcher, I am always excited by research that improves the lives of children and adolescents. This study provides valuable evidence that once-daily atomoxetine is a safe and effective treatment option for ADHD, paving the way for improved management of this complex condition. It is a testament to the power of scientific research to improve the well-being of our children.

Date :
  1. Date Completed 2002-12-04
  2. Date Revised 2022-03-17
Further Info :

Pubmed ID

12411225

DOI: Digital Object Identifier

10.1176/appi.ajp.159.11.1896

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.